According to GuruFocus Insider Data, the recent CFO buys were: Hanesbrands Inc. (HBI, Financial), Sprouts Farmers Market Inc. (SFM, Financial) and Aquestive Therapeutics Inc. (AQST, Financial).
Hanesbrands Inc. (HBI, Financial): CFO Barry Hytinen bought 10,100 shares
CFO Barry Hytinen bought 10,100 shares for $14.59 per share on Nov. 20. Since then, the stock price has increased by 9.05%. Hanesbrands Inc. has a market cap of $5.74 billion and its shares were traded around $15.91. The company has a P/E ratio of 397.75 and P/S ratio of 0.87. The trailing 12-month dividend yield of Hanesbrands Inc. stocks is 3.77%, while the forward dividend yield is 3.77%. Over the past 10 years, Hanesbrands Inc. had an annual average earnings growth of 6.40%.
Hanesbrands announced its third-quarter results with revenue of $1.85 billion and gross profit of $724.43 million, while the net income was $171.42 million. The 2017 total revenue was $6.47 billion, a 7% increase from 2016. The 2017 gross profit was $2.56 billion, a 10% increase from the year prior. The 2017 net income was $61.89 million.
CEO Gerald Evans bought 6,500 shares for $14.98 per share on Nov. 19. Since then, the stock price has increased by 6.21%. Director Ronald L Nelson bought 20,000 shares for $14.83 per share on Nov. 19. Since then, the stock price has increased by 7.28%. Director Jessica Tuchman Mathews sold 2,115 shares for $16.54 per share on Nov. 12. Since then, the stock price has decreased by 3.81%.
Sprouts Farmers Market Inc. (SFM, Financial): Interim Co-CEO and CFO Bradley Lukow bought 10,000 shares
Interim Co-CEO and CFO Bradley Lukow bought 10,000 shares for $23.09 per share on Nov. 30. Since then, the stock price has decreased by 0.3%. Sprouts Farmers Market Inc. has a market cap of $2.94 billion and its shares were traded around $23.02 with a P/E ratio of 16.47 and P/S ratio of 0.60. Over the past 5 years, Sprouts Farmers Market Inc. had an annual average earnings growth of 23.30%.
Sprouts Farmers Market announced its third-quarter results with revenue of $1.33 billion and gross profit of $382.38 million, while the net income was $37.50 million. The 2017 total revenue was $4.66 billion, a 15% increase from 2016. The 2017 gross profit was $1.35 billion, a 14% increase from the year prior. The 2017 net income was $158.44 million.
CEO Amin N. Maredia sold 165,213 shares for $27.52 per share on Nov. 19. Since then, the stock price has decreased by 16.35%. Director Shon A. Boney bought 88,500 shares for $22.83 per share on Nov. 30. Since then, the stock price has increased by 0.83%. Chief Merchandising Officer David Mcglinchey bought 5,000 shares for $23.1 per share on Nov. 30. Since then, the stock price has decreased by 0.35%.
Aquestive Therapeutics Inc. (AQST, Financial): SVP-CFO John T. Maxwell bought 10,000 shares
SVP-CFO John T. Maxwell bought 10,000 shares for $9.8 per share on Nov. 21. Since then, the stock price has decreased by 12.35%. Aquestive Therapeutics Inc. has a market cap of $214.253 million and its shares were traded around $8.59. The company has P/S ratio of 2.93.
Aquestive Therapeutics announced its third-quarter results with revenue of $13.27 million and gross profit of $7.68 million, while the net loss was $15.04 million. The 2017 total revenue was $66.92 million, a 29% increase from 2016. The 2017 gross profit was $47.10 million, a 33% increase from the year prior. The 2017 net loss was $11.42 million.
CEO and President Keith J. Kendall bought 1,000 shares for $9.87 per share on Nov. 27. Since then, the stock price has decreased by 12.97%. General Counsel Lori J .Braender bought 1,000 shares for $10.57 per share on Nov. 27. Since then, the stock price has decreased by 18.73%. SVP-HR and Org. Development Theresa Wood bought 500 shares for $10.34 per share on Nov. 26. Since then, the stock price has decreased by 16.92%.
Disclosure: None.
